HCW Biologics restates Q1 EPS, cutting net income attributable to common shareholders by USD 728,000
HCWB•HCWB•HCWB•HCWB•Total net income stayed USD 3.47 million; cash flows, assets, liabilities, and equity were unchanged since the adjustment only reallocated earnings.
HCW Biologics filed restated quarterly results for the three months ended March 31, 2026 in a Form 10-Q/A.
The restatement corrected earnings-per-share under ASC 260, treating certain common warrants as participating securities under the two-class method.
Net income attributable to common stockholders fell by about USD 728,000 to USD 1.26 million.
Basic and diluted EPS dropped by USD 0.8 to USD 1.39, reflecting a one-for-six reverse stock split effective June 30, 2026.
